Armata Pharmaceuticals, Inc.
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$173.8M
- Total assets
- $76.9M
- Market cap
- $275.3M
- Operating margin
- -747.0%
- Net margin
- -3544.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.9M
- Operating expenses
- $41.5M
- Operating income
- -$36.6M
- Net income
- -$173.8M
- EPS (basic)
- $-4.80
- EPS (diluted)
- $-4.80
Balance sheet
- Total assets
- $76.9M
- Current assets
- $10.7M
- Total liabilities
- $295.5M
- Current liabilities
- $8.9M
- Shareholders’ equity
- -$218.6M
Cash flow
- Operating cash flow
- -$25.8M
- Investing cash flow
- -$542.0K
- Financing cash flow
- $25.6M
- Net cash flow
- -$693.0K
Statements via Polygon.io (SEC filings)
- Market cap
- $275.3M
- EPS (diluted)
- $-4.8
- Shares outstanding
- 36.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 27, 1994
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $173.8M.
- Revenue grew 10% from FY2021 to FY2025.
- Trading 49% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Armata Pharmaceuticals, Inc..
Write a review
News about Armata Pharmaceuticals, Inc.
News & sentiment via Polygon.io
